REG - Angle PLC - Notice of Results

AngleAnnouncement

23/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250523:nRSW8796Ja&default-theme=true

RNS Number : 8796J  Angle PLC  23 May 2025

 For immediate release  23 May 2025

 

ANGLE plc ("the Company")

 

Notice of Preliminary Results and Webcast

 

ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company with
innovative circulating tumour cell (CTC) diagnostic solutions for use in
research, drug development and clinical oncology, will be releasing its
preliminary results for the year ended 31 December 2024 on Wednesday 28 May
2025.

 

A meeting for analysts will be held at 11:00 am BST on Wednesday 28 May 2025
at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London,
EC1A 4HD.

 

A live webcast of the analyst meeting can be accessed via ANGLE's Investor
Centre page, https://angleplc.com/investor-relations/corporate-presentations/
(https://angleplc.com/investor-relations/corporate-presentations/) , with
Q&A participation reserved for analysts only. Please register in advance
and log on to the webcast approximately 5 minutes before 11:00 am on the day
of the results. A recording of the webcast will be made available on ANGLE's
website following the results meeting.

 

For further information:

 

 ANGLE plc                                +44 (0) 1483 343434
 Andrew Newland, Chief Executive

 Ian Griffiths, Finance Director

 Berenberg (NOMAD and Corporate Broker)   +44 (0) 20 3207 7800

 Toby Flaux, Ciaran Walsh, Milo Bonser

 FTI Consulting

 Simon Conway, Sam Purewal                +44 (0) 203 727 1000

 Matthew Ventimiglia (US)                 +1 (212) 850 5624

 

 

For Frequently Used Terms, please see the Company's website on
https://angleplc.com/investor-relations/glossary/
(https://angleplc.com/investor-relations/glossary/)

 

Notes for editors

 

About ANGLE plc

 

ANGLE is a world-leading liquid biopsy company with innovative circulating
tumour cell (CTC) solutions for use in research, drug development and clinical
oncology using a simple blood sample. ANGLE's FDA cleared and patent protected
CTC harvesting technology known as the Parsortix(®) PC1 System enables
complete downstream analysis of the sample including whole cell imaging and
proteomic analysis and full genomic and transcriptomic molecular analysis.

 

ANGLE's commercial businesses are focusing on clinical services and diagnostic
products. The clinical services business is offered through ANGLE's
GCLP-compliant laboratories. Services include custom made assay development
and clinical trial testing for pharma. Products include the Parsortix system,
associated consumables and assays.

 

Over 100 peer-reviewed publications have demonstrated the performance of the
Parsortix system. For more information, visit www.angleplc.com
(http://www.angleplc.com)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORDGGDUIBDDGUD